Home › Medical › Cannabis and Refractory Epilepsy
⚐ Flag an error How this page was made
Also known as: drug-resistant epilepsy and cannabis · CBD for Dravet syndrome · CBD for Lennox-Gastaut syndrome

Cannabis and Refractory Epilepsy

Evidence on pharmaceutical CBD for drug-resistant seizures and what remains unproven.

Automated fact-check pass
16 cited sources
Published
Last reviewed
How this page was made

This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.

↯ The honest take

Pharmaceutical CBD (Epidiolex) has solid trial data for three rare childhood syndromes—Dravet, Lennox-Gastaut, and tuberous sclerosis complex—but the seizure reductions are modest and incomplete. For everything else (THC, whole-plant extracts, artisanal CBD oils, adult epilepsy), the evidence either doesn't exist or comes from uncontrolled studies that can't prove causation. Dispensary wisdom about ratios and 'entourage effects' is not backed by clinical trials.

Not Medical Advice

This article is not medical advice. Refractory epilepsy is a serious neurological condition requiring specialist care. Do not start, stop, or change anti-seizure medications based on what you read here or anywhere else online. Pharmaceutical cannabidiol (CBD) interacts with several common anti-seizure drugs—notably clobazam and valproate—and requires neurologist supervision and monitoring of liver enzymes. Always work with a neurologist or epileptologist before considering any cannabis-derived product.

Plain-Language Summary

Refractory (or drug-resistant) epilepsy means seizures that do not respond to two or more appropriately chosen and properly dosed anti-seizure medications [1]. It affects roughly one-third of people with epilepsy [1].

Of all the cannabis-related interventions studied in rigorous trials, only one has clear evidence: purified pharmaceutical cannabidiol (CBD), sold as Epidiolex in the US and Epidyolex in Europe. In randomized controlled trials, it reduced seizure frequency in three specific syndromes—Dravet syndrome, Lennox-Gastaut syndrome, and seizures associated with tuberous sclerosis complex—significantly enough to win FDA and EMA approval [2][3][4][5]. Strong evidence

These approvals represent the complete set of strong evidence. Everything beyond them—THC, whole-plant extracts, artisanal CBD oils, CBD for adult focal epilepsy, and specific cannabinoid ratios—sits somewhere between "promising but unproven" and "folklore without controlled support."

What Probably Works: Pharmaceutical CBD for Three Syndromes

Dravet syndrome (severe myoclonic epilepsy of infancy).

A 2017 landmark NEJM trial showed that at 20 mg/kg/day, CBD reduced median convulsive seizures from 12.4 to 5.9 per month, compared with 14.9 to 14.1 on placebo [2]. Strong evidence About 5% of patients became seizure-free during the trial period; responders showed a median 42% reduction in seizure frequency [2].

Lennox-Gastaut syndrome.

Two large randomized trials showed roughly 40–45% reductions in drop seizures (atonic seizures) on CBD versus ~20% on placebo [3][4]. Strong evidence Again, seizure freedom was rare; most patients remained partially responsive but improved.

Tuberous sclerosis complex (TSC).

A 2021 randomized trial showed seizure frequency reductions of approximately 48% on CBD versus 27% on placebo [5]. Strong evidence This trial is notable because it enrolled patients regardless of prior clobazam use, clarifying that CBD has benefit beyond drug-interaction effects.

Mechanism and persistence of effect.

The mechanism by which CBD reduces seizures is not fully understood. CBD is not a strong agonist at CB1 or CB2 receptors; proposed targets include GPR55, TRPV1, and enhanced adenosine tone [7]. Long-term open-label follow-up data suggest that in responders, benefit persists for at least several years, though tolerance has been observed in some patients [6].

What Might Work: Weaker or Disputed Evidence

CBD for other refractory epilepsies.

Open-label studies and expanded-access programs report possible benefit in CDKL5 deficiency disorder, Aicardi syndrome, Doose syndrome, and various focal epilepsies [8]. Weak / limited These are uncontrolled observational data—no placebo group, often no blinding—so effect sizes cannot be reliably separated from placebo response, observer bias, or natural fluctuation in seizure frequency.

Artisanal and full-spectrum CBD oils.

Some observational reports describe seizure reductions in patients using commercial CBD products [9]. However, products vary markedly in actual CBD content, THC contamination, and pesticide or heavy metal residues. In a 2017 study, 26 of 84 commercial CBD products (31%) contained substantially less CBD than labeled, and some contained detectable THC despite labeling [9]. Weak / limited If an effect exists, the dose and purity cannot be reliably reproduced, making clinical outcomes unpredictable.

Cannabidivarin (CBDV).

Preclinical and animal data are encouraging, but a Phase 2 trial in adult focal seizures did not meet its primary efficacy endpoint [10]. Weak / limited CBDV remains investigational.

The 'entourage effect' in epilepsy.

A frequently cited 2018 narrative review suggested that CBD-rich extracts might outperform purified CBD [11]. Disputed However, the analysis pooled heterogeneous open-label and observational studies with different doses, patient populations, and outcome measures—not a controlled head-to-head comparison. No randomized trial has demonstrated that a whole-plant extract beats purified CBD in refractory epilepsy.

What Doesn't Work or Lacks Evidence

THC as an anti-seizure agent.

Despite popular claims, rigorous controlled evidence that THC reduces seizures in humans is essentially absent. Animal studies show mixed results, and THC can be proconvulsant (seizure-promoting) at higher doses [12]. Weak / limited No RCT has shown THC efficacy in human refractory epilepsy.

Specific CBD:THC ratios (20:1, 18:1, etc.).

These marketing constructs are not supported by clinical trial data No data. They originated in dispensary practice and cannabis-testing guidelines, not in controlled pharmacology studies.

Smoked or vaporized cannabis flower for seizures.

No randomized trials support inhaled cannabis flower as an anti-seizure intervention No data. Pediatric inhalation of cannabis is contraindicated by medical organizations and regulatory bodies.

CBD as monotherapy (replacement for standard drugs).

All pivotal trials tested CBD as add-on therapy to existing anti-seizure medications [2][3][4][5]. There is no good evidence that CBD alone replaces standard anti-seizure drugs No data. It is not approved or studied as a first-line or monotherapy option.

What We Don't Know

Comparison with Standard Treatments

For the three syndromes where CBD has strong evidence, other established add-on options include:

Dravet syndrome: Stiripentol, clobazam, valproate, fenfluramine, and levetiracetam. Fenfluramine has produced larger median seizure reductions than CBD in observational comparisons; notably, a 2019 RCT showed fenfluramine reduced convulsive seizures by a median of 73%, substantially more than CBD's 42% [13]. Strong evidence However, fenfluramine carries a lower incidence of liver enzyme elevation than valproate-CBD combinations.

Lennox-Gastaut syndrome: Rufinamide, clobazam, valproate, lamotrigine, topiramate, the ketogenic diet, vagus nerve stimulation, and corpus callosotomy.

Tuberous sclerosis complex seizures: Everolimus (an mTOR inhibitor that targets the underlying genetic defect), plus standard anti-seizure agents.

CBD is not a first-line replacement for these options. It is an add-on choice when seizures remain uncontrolled despite these agents, selected partly based on prior medication history, drug-interaction risk, side-effect profile, and patient/family preference. The ketogenic diet remains an underused, evidence-based option for refractory pediatric epilepsy and should not be bypassed in favor of cannabinoids without explicit consideration [14]. Strong evidence

Risks, Adverse Effects, and Drug Interactions

Adverse effects in trials.

Pharmaceutical CBD is not benign. In pivotal trials, common adverse effects included somnolence, decreased appetite, diarrhea, fatigue, rash, and elevated liver transaminases (alanine aminotransferase and aspartate aminotransferase) [2][3][4][5]. Strong evidence Liver enzyme elevations were more frequent and severe in patients also taking valproate, a known hepatotoxic drug Strong evidence.

Major drug interactions.

Clobazam. CBD inhibits the CYP2C19 and CYP3A4 enzymes, raising concentrations of N-desmethylclobazam (the active metabolite of clobazam) [15]. Strong evidence Some of CBD's apparent anti-seizure benefit in early trials may partly reflect boosted clobazam exposure through this mechanism. However, the tuberous sclerosis trial showed CBD efficacy independent of clobazam use, suggesting a genuine effect beyond drug interaction [5].

Valproate. Combined CBD and valproate use is associated with increased risk of hepatotoxicity Strong evidence. Monitoring of liver enzymes is essential.

Warfarin, tacrolimus, and other CYP2C19/3A4 substrates. CBD can shift levels unpredictably, requiring dose adjustment or therapeutic drug monitoring Weak / limited.

Risks specific to unregulated CBD products.

Artisanal and commercial CBD oils add risks the pharmaceutical version does not: inaccurate labeling (underestimating or overestimating CBD content), pesticide or heavy metal contamination, and unintended THC content [9][16]. Strong evidence In children, accidental ingestion of mislabeled high-THC products has caused hospitalization [16].

How to Evaluate Claims About Cannabis and Epilepsy

When you encounter claims about cannabis or CBD for epilepsy, ask:

  1. Is this from a randomized controlled trial? Anecdotes, case reports, and open-label studies cannot prove causation.
  2. Which condition? CBD evidence is specific to Dravet, Lennox-Gastaut, and TSC-associated seizures. Claims for other epilepsies need controlled data.
  3. Is it pharmaceutical-grade CBD (Epidiolex) or unregulated product? Laboratory testing shows many commercial products mislabeled.
  4. Who has a financial stake? Dispensary staff, influencers, and supplement vendors profit from sales; academic research and regulatory agencies have different incentives.
  5. Are drug interactions addressed? Responsible medical practitioners always discuss CYP interactions with clobazam and valproate.

For Cannabis and Polypharmacy Risks, see also Cannabis in Pediatric Epilepsy.

Sources

  1. Peer-reviewed Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069–1077.
  2. Peer-reviewed Devinsky O, Cross JH, Laux L, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. New England Journal of Medicine. 2017;376(21):2011–2020.
  3. Peer-reviewed Devinsky O, Patel AD, Cross JH, et al. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. New England Journal of Medicine. 2018;378(20):1888–1897.
  4. Peer-reviewed Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085–1096.
  5. Peer-reviewed Thiele EA, Bebin EM, Bhathal H, et al. Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. JAMA Neurology. 2021;78(3):285–292.
  6. Peer-reviewed Laux LC, Bebin EM, Checketts D, et al. Long-term safety and efficacy of cannabidiol in children and adults with treatment-resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Epilepsy Research. 2019;154:13–20.
  7. Peer-reviewed Gray RA, Whalley BJ. The proposed mechanisms of action of CBD in epilepsy. Epileptic Disorders. 2020;22(S1):S10–S15.
  8. Peer-reviewed Devinsky O, Verducci C, Thiele EA, et al. Open-label use of highly purified CBD (Epidiolex) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy & Behavior. 2018;86:131–137.
  9. Peer-reviewed Bonn-Miller MO, Loflin MJE, Thomas BF, et al. Labeling Accuracy of Cannabidiol Extracts Sold Online. JAMA. 2017;318(17):1708–1709.
  10. Reported GW Pharmaceuticals. Cannabidivarin (GWP42006) did not differentiate from placebo in a Phase 2a study in adult patients with inadequately controlled focal seizures. Press release, 22 September 2018.
  11. Peer-reviewed Pamplona FA, da Silva LR, Coan AC. Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. Frontiers in Neurology. 2018;9:759.
  12. Peer-reviewed Rosenberg EC, Tsien RW, Whalley BJ, Devinsky O. Cannabinoids and Epilepsy. Neurotherapeutics. 2015;12(4):747–768.
  13. Peer-reviewed Lagae L, Sullivan J, Knupp K, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10216):2243–2254.
  14. Peer-reviewed Neal EG, Chaffe H, Schwartz RH, et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurology. 2008;7(6):500–506.
  15. Peer-reviewed Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246–1251.
  16. Government U.S. Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD): Consumer Update and Warning Letters. FDA.gov.

How this page was made

Generation history

Oct 30, 2026
Revision
Oct 30, 2026
Fact-check pass — raised 7 flags
May 12, 2026
Fact-check pass — raised 2 flags
May 12, 2026
Initial draft

Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.